Payment overview · 2025
General Payments
$412.95
17 reported records · 9 companies
Healthcare provider profile · identity verified
Joseph Angelo Caruana, DO
Allopathic & Osteopathic Physicians|Family Medicine · BROOKLYN, NY · NPI 1669451498
Verified facts
What the public records show
CMS Open Payments records show Joseph Angelo Caruana, DO received $412.95 in general payments during 2025 across 17 reported records.
ABBVIE INC. accounted for 32.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $133.73 | 32.4% | 6 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $61.79 | 15.0% | 2 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $48.14 | 11.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $39.18 | 9.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.30 | 8.1% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $27.87 | 6.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $26.74 | 6.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $24.59 | 6.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.61 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $412.95 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $133.73 | 6 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $61.79 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $56.79 | 3 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $48.14 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $27.87 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $27.87 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $27.87 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $26.74 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $26.74 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $24.59 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 169 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
93 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
66 | 15 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
169 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 497 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 479 | 128 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 443 | 121 |
| Metoprolol Succinate | Metoprolol Succinate | 387 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 323 | 79 |
| Simvastatin | Simvastatin | 283 | 83 |
| Famotidine | Famotidine | 247 | 75 |
| Losartan Potassium | Losartan Potassium | 243 | 66 |
| Omeprazole | Omeprazole | 234 | 75 |
| Sertraline Hcl | Sertraline Hcl | 207 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 206 | 65 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 202 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 196 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 171 | 58 |
| Eliquis | Apixaban | 169 | 33 |
| Metformin Hcl Er | Metformin Hcl | 163 | 47 |
| Mounjaro | Tirzepatide | 152 | 23 |
| Furosemide | Furosemide | 139 | 40 |
| Trazodone Hcl | Trazodone Hcl | 135 | 34 |
| Donepezil Hcl | Donepezil Hcl | 133 | 40 |
| Memantine Hcl | Memantine Hcl | 130 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 51 |
| Lisinopril | Lisinopril | 128 | 38 |
| Enalapril Maleate | Enalapril Maleate | 117 | 31 |
| Meloxicam | Meloxicam | 111 | 51 |
| Allopurinol | Allopurinol | 104 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 27 |
| Synthroid | Levothyroxine Sodium | 93 | 23 |
| Jardiance | Empagliflozin | 91 | 28 |
| Carvedilol | Carvedilol | 90 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 19 |
| Ezetimibe | Ezetimibe | 79 | 30 |
| Azithromycin | Azithromycin | 75 | 62 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 21 |
| Trulicity | Dulaglutide | 69 | 15 |
| Finasteride | Finasteride | 67 | 19 |
| Montelukast Sodium | Montelukast Sodium | 66 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 63 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 17 |
| Gabapentin | Gabapentin | 59 | 23 |
| Metformin Hcl | Metformin Hcl | 59 | 21 |
| Valsartan | Valsartan | 58 | 11 |
| Xarelto | Rivaroxaban | 55 | suppressed |
| Prednisone | Prednisone | 53 | 33 |
| Alprazolam | Alprazolam | 52 | 27 |
| Ketoconazole | Ketoconazole | 52 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 17 |
| Alendronate Sodium | Alendronate Sodium | 49 | 15 |
| Januvia | Sitagliptin Phosphate | 49 | 11 |
| Ramipril | Ramipril | 47 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | 15 |
| Glimepiride | Glimepiride | 44 | 13 |
| Buspirone Hcl | Buspirone Hcl | 41 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 28 |
| Verapamil Er | Verapamil Hcl | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | 24 |
| Ozempic | Semaglutide | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 38 | suppressed |
| Cephalexin | Cephalexin | 37 | 28 |
| Potassium Chloride | Potassium Chloride | 37 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Cefdinir | Cefdinir | 35 | 32 |
| Celecoxib | Celecoxib | 35 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 28 |
| Raloxifene Hcl | Raloxifene Hcl | 33 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 32 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Diazepam | Diazepam | 29 | 11 |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 25 |
| Clonazepam | Clonazepam | 27 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 21 |
| Tramadol Hcl | Tramadol Hcl | 25 | 12 |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 20 | 12 |
| Digoxin | Digoxin | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Tradjenta | Linagliptin | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | 11 |
| Pentoxifylline | Pentoxifylline | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Tegretol | Carbamazepine | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $412.95 · 17 records | ABBVIE INC. | ELIQUIS, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, NURTEC ODT, Ohtuvayre, QULIPTA, REXULTI, SHINGRIX, SMARTVEST, TRELEGY ELLIPTA, UBRELVY | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error